Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | ESMO 2023 sarcoma updates: MEDISARC and TOMAS2

Breelyn Wilky, MD, University of Colorado Anschutz Medical Campus, Aurora, CO, provides an overview of the Phase II MEDISARC trial (NCT03317457), which assessed durvalumab and tremelimumab in patients with advanced or metastatic soft tissue sarcoma. The investigational therapy was found to have similar clinical activity in patients compared to doxorubicin. Dr Wilky additionally discusses the Phase II TOMAS2 trial (NCT03838744) of trabectedin with or without olaparib, a PARP inhibitor, in patients with soft tissue sarcomas (STS). Addition of olaparib was found to improve outcomes in patients with DNA repair defects. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.